Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH2 | P25021 | 1/20 | 0.55 |
| ▸ | HRH1 | P35367 | 1/20 | 0.55 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.53 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.49 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9292241 | 0.89 | CHRM3 (0.67) | HRH2HRH1CHRM3CHRM1OPRK1 | |
| SCHEMBL4984605 | 0.88 | CHRM1 (0.66) | HRH2HRH1CHRM1ROCK2CYP3A4 | |
| SCHEMBL18390259 | 0.83 | CHRM1 (0.61) | HRH2HRH1CHRM3CHRM1ROCK2 | |
| Hydrochloric Acid SCHEMBL21995057 | 0.83 | ROCK2 (0.54) | HRH2HRH1CHRM3CHRM1ROCK2 | |
| Hydrochloric Acid SCHEMBL21995059 | 0.83 | ROCK2 (0.54) | HRH2HRH1CHRM3CHRM1ROCK2 | |
| SCHEMBL5007669 | 0.78 | DPP4 (0.54) | HRH2HRH1CHRM3CHRM1ROCK2 | |
| SCHEMBL14027830 | 0.78 | DPP4 (0.54) | HRH2HRH1CHRM3CHRM1ROCK2 | |
| SCHEMBL18704999 | 0.78 | CHRM1 (0.63) | CHRM1HRH3ROCK2CYP3A4MEN1 | |
| SCHEMBL22642320 | 0.77 | ROCK2 (0.50) | HRH2HRH1CHRM3CHRM1ROCK2 | |
| Hydrochloric Acid SCHEMBL4741021 | 0.77 | DPP4 (0.52) | HRH2HRH1CHRM3CHRM1ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7468378-B2 | Substituted quinoline compounds | PFIZER INC. (US) | 2008-12-23 | — | — | US | disclosed |
| US-7393958-B2 | Triamide-substituted heterobicyclic compounds | PFIZER, INC. (US) | 2008-07-01 | — | — | US | disclosed |
| US-7368573-B2 | Triamide-substituted heterobicyclic compounds | PFIZER INC. (US) | 2008-05-06 | — | — | US | disclosed |
| US-20070093525-A1 | Triamide-substituted heterobicyclic compounds | PFIZER INC | 2007-04-26 | — | — | US | disclosed |
| US-20060223851-A1 | TRIAMIDE-SUBSTITUTED HETEROBICYCLIC COMPOUNDS | BERTINATO PETER | 2006-10-05 | — | — | US | disclosed |
| US-20050234099-A1 | Substituted quinoline compounds | PFIZER INC | 2005-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234099-A1 | Substituted quinoline compounds | APOB, APOL1, MTPN | HRH2 1182/4885HRH1 1159/4885CHRM3 1283/4885 |
| US-20060223851-A1 | TRIAMIDE-SUBSTITUTED HETEROBICYCLIC COMPOUNDS | APOB, MTPN, CTRB1 | HRH2 1207/4885HRH1 1309/4885CHRM3 2709/4885 |
| US-20070093525-A1 | Triamide-substituted heterobicyclic compounds | APOB, MTPN, CTRB1 | HRH2 1207/4885HRH1 1309/4885CHRM3 2709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.